Navigation Links
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Date:9/21/2009

ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Neuralstem is the first company to commence a stem cell trial to treat ALS. The trial will study the safety of Neuralstem's cells and the surgical procedures and devices required for multiple injections of Neuralstem's cells directly into the grey matter of the spinal cord. The FDA's approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.

Neuralstem CEO and President, Richard Garr, stated, "The beginning of our clinical trial program is a major step towards achieving Neuralstem's goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process. This trial will be in the extremely capable hands of Dr. Eva L. Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, and Dr. Jonathan Glass, Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, world
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Respiratory therapy students will soon ... of life-like respiratory ailments using the latest in ... Rapids-based, Michigan Instruments Inc. developers of the world-renowned ... respiratory simulation units to the pro-gram, which cost ... Muskegon Community College are collaborating to offer Muskegon’s ...
(Date:11/21/2014)... TRU-D SmartUVC LLC and its UK partners, Rapid Disinfection ... TRU-D SmartUVC, at FIS 2014 in Harrogate, England ... Stand 23. The conference, hosted by Federation of ... largest infection-related event of its kind and brings together more ... events of its type throughout the world. This annual event ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... the Predictable Relief Provided by the Only Commercially Available ... ... in Adults, DEERFIELD, Ill., Nov. 6 Takeda Pharmaceuticals ... the first direct-to-consumer (DTC) advertising campaign for AMITIZA(R),(lubiprostone), the only ...
... HORSHAM, Pa. and KENILWORTH, N.J., Nov. 6 ... Pharma Corporation,announced today that an estimated one ... (infliximab), the leading anti-tumor necrosis,factor (TNF)-alpha therapy ... to,treat more patients worldwide than all other ...
... and VALAIS, Switzerland, Nov. 5 ,Lantibio, Inc. and TRB ... a subsidiary of Alcon, Inc. (NYSE: ACL ) ... Eye Syndrome product. The,product consists of a TRB patented ... the US under an IND by a,subsidiary of Lantibio. ...
Cached Biology Technology:'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down 2'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down 3'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 2Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 3Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug 4
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... the University of Saskatchewan has discovered a signaling pathway in ... for blocking its action, that may point to a single ... the March issue of the prestigious journal Nature Medicine. , ... U of S department of psychiatry, found that a naturally ...
... the Forsyth Institute have discovered a new mechanism responsible ... locate themselves on the left or right side of ... mechanism, garnered through the study of three different vertebrates ... a single common mechanism has been identified in left-right ...
... Scientists generally agree that all cloned animals are biologically ... for stem cells derived from cloned embryos, the basis ... cell nuclear transfer, therapeutic cloning is a promising approach ... disorders. Demonstrated in mice but not in humans, it ...
Cached Biology News:Team discovers possible 'universal strategy' to combat addiction 2Forsyth scientists gain greater understanding of how embryos differentiate left from right 2Forsyth scientists gain greater understanding of how embryos differentiate left from right 3Cloned stem cells prove identical to fertilized stem cells 2Cloned stem cells prove identical to fertilized stem cells 3
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: